FDA.reportPublic FDA data

Oseni 25/30 Oral Tablet

RxCUI
1368437
RxNorm name
Oseni 25/30 Oral Tablet
Display name
Oseni 25/30 Oral Tablet
Full name
Oseni 25/30 Oral Tablet
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:38:57

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
OSENIALOGLIPTIN AND PIOGLITAZONETakeda Pharmaceuticals America, Inc.4c619ed9-fe3e-4158-9938-80c6c3493d552025-02-28Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 1368437

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
4c619ed9-fe3e-4158-9938-80c6c3493d55Oseni 25 MG / 30 MG Oral Tablet [PSN] · alogliptin 25 MG / pioglitazone 30 MG Oral Tablet [Oseni] [SBD] · Oseni 25/30 (as alogliptin benzoate 34 MG / pioglitazone hydrochloride 33.06 MG) Oral Tablet [SY] · Oseni 25/30 Oral Tablet [SY]423These highlights do not include all the information needed to use OSENI ® safely and effectively. See full prescribing information for OSENI. OSENI (alogliptin and pioglitazone) tablets, for oral use Initial U.S. Approval: 201320250228